Fig. 4From: CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumabROC curves of the combination of CA19-9 and P-CRP for the irAEs CA19-9, carbohydrate antigen 19–9; irAEs, immune-related adverse events; P-CRP, platelet count × serum C-reactive protein level multiplier value; ROC, receiver operating characteristicBack to article page